In double-blind, placebo-controlled trials, daily application of GHK-Cu cream at 3% concentration for 12 weeks produced a 70% increase in skin collagen thickness as measured by ultrasound imaging, a 40% increase in skin elasticity, and visible reduction in fine lines and wrinkles
Preclinical studies suggest BPC-157 may support gastrointestinal healing, tendon and ligament repair, and wound closure in animal models
Our team has rounded up the best ways to banish them for good
Dosage according to clinical trials: In clinical studies, Selank has been administered intranasally in doses of up to 2700mcg (equivalent to 36 drops) divided into three daily applications for up to 21 days, followed by a washout period [15]
Approval Timeline and Availability CagriSema: Ahead in the Race FDA Submission: December 18, 2025 (NDA filed) Expected FDA Decision: Q4 2026 or Q1 2027 Predicted Launch: Mid-2027 Advantage: 6-12 month head start on retatrutide REDEFINE Program Status: REDEFINE-1: Completed (obesity, 20.4% weight loss) REDEFINE-2: Completed (type 2 diabetes, 13.7% weight loss) REDEFINE-3: Ongoing (cardiovascular outcomes trial) REDEFINE-8: Ongoing (body composition study) High-dose CagriSema (2.4/7.2mg): Starting late 2026 Retatrutide: More Trials Needed FDA Submission: Expected Q4 2026 or Q1 2027 Expected FDA Decision: Late 2027 Predicted Launch: Q1-Q2 2028 TRIUMPH Program Status: TRIUMPH-4: Completed (osteoarthritis, 28.7% weight loss) TRIUMPH-1: Complete 28.3% weight loss (May 2026) TRIUMPH-2: Expected Q3Q4 2026 (obesity + type 2 diabetes) TRIUMPH-3: Expected later 2026 (obesity + cardiovascular disease) TRIUMPH-6: Weight maintenance trial (ongoing) Disadvantage: Needs more trials before submission, 6-12 month delay vs CagriSema
How long does it take to feel relief after PRP therapy
